Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-05-17 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
Regulatory Filings Classification · 1% confidence The document is an announcement by Ipsen detailing new data on its drug Bylvay to be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). It focuses on scientific presentations, abstracts, study details (ASSERT, PEDFIC), and contact information for investors and media. This content structure—announcing participation in a scientific/industry meeting and presenting research findings—is characteristic of an Investor Presentation (IP) or a general press release about scientific progress, rather than a formal regulatory filing like a 10-K, ER, or IR. Since it is a detailed presentation of data and strategy aimed at investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, although it functions as a press release announcing conference participation.
2023-05-17 English
Ipsen présentera de nouvelles données sur Bylvay® (odévixibat) lors du congrès annuel ESPGHAN, attestant de son engagement à faire progresser le traitement des maladies cholestatiques rares
Regulatory Filings Classification · 1% confidence The document is a press release dated May 17, 2023, announcing that Ipsen will present new data on its drug Bylvay® at the ESPGHAN annual congress (May 17-20, 2023). It details the abstracts to be presented, including oral presentations, posters, and e-posters, focusing on clinical trial results (ASSERT, PEDFIC studies). This content is characteristic of a company communicating upcoming scientific presentations or data disclosures, often preceding or coinciding with a major medical conference. It is not a formal regulatory filing (like 10-K or IR), nor is it a full earnings release (ER) or a transcript (CT). Since it is an announcement about data being presented at a scientific meeting, it fits best under the category of Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if no better fit exists. Given the detailed breakdown of presentations and scientific context, 'Investor Presentation' (IP) is the most appropriate classification, as these materials are often repurposed or released to investors alongside scientific updates. It is not a general 'Report Publication Announcement' (RPA) because it is announcing *content* (data presentation) rather than the publication of a formal statutory report.
2023-05-17 French
Ipsen SA - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social - avril 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a monthly update (as of April 30, 2023) detailing the total number of shares and the total gross and net voting rights. This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the composition of the capital and voting rights, SHA is the most precise fit among the defined categories, as it concerns the capital structure components.
2023-05-10 French
Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and explicitly references French regulatory articles (AMF). It provides a table detailing the total number of shares and voting rights as of a specific date (April 30, 2023). This type of periodic disclosure regarding the composition of share capital and voting rights is a specific regulatory filing requirement, often related to major shareholdings or capital structure transparency, but it does not fit perfectly into the defined categories like 10-K, ER, or DIV. It is a specific regulatory disclosure concerning share capital structure and voting rights. Given the options, it is closest to a general regulatory filing (RNS) or perhaps a specific notification related to share capital changes, but since it is a recurring monthly disclosure about the total number of shares and voting rights, it is best classified as a Regulatory Filing (RNS) as it is a mandatory disclosure that doesn't fit the other specific financial or corporate action codes. It is not a Major Shareholding Notification (MRQ) as it reports the total, not a change crossing a threshold by a specific entity, although it provides the basis for such calculations.
2023-05-10 English
Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting
AGM Information Classification · 1% confidence The document explicitly announces the details for the 'Combined Shareholders' Meeting of Ipsen' scheduled for May 31, 2023. It discusses the formalities for making preparatory documents available, the agenda (including dividend approval and director renewals), and refers to the 'notice of Meeting' (*avis de convocation*). This content is directly related to soliciting shareholder participation and providing necessary information ahead of the Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (3230 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2023-05-10 English
IPSEN : AGM 2023 - Modalités de mise à disposition des documents préparatoires à l'Assemblée
AGM Information Classification · 1% confidence The document title explicitly mentions 'INFORMATIONS CONCERNANT LA TENUE DE L'ASSEMBLEE GENERALE MIXTE DU 31 MAI 2023' (Information concerning the holding of the Combined General Meeting of May 31, 2023). It details the date, location, and the documents available for the meeting, including the agenda and proposed resolutions (like dividend approval and director mandates). This content is directly related to the preparation for and information surrounding the Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2023-05-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.